403 results about "Phosphatidylserine" patented technology

The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

Formulations or delivery systems are provided for controlled release of therapeutically active agents. The delivery systems are composed of polymer and lipid materials and may be prepared as a gel, paste, solution, film, implant or barrier depending on the intended application. The polymer component of the matrix is the naturally occurring biomaterial, chitosan, or a mixture of chitin and chitosan. The lipid component may include phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidyl or a mixture thereof. The delivery system may be used for delivery of hydrophilic agents, hydrophobic agents or combinations thereof. The therapeutically active agents may be formulated within the matrix as free agents or incorporated into particles. In a preferred embodiment the agents are incorporated into polymeric particles that are dispersed throughout the matrix.

Disclosed herein are alternative, enhanced, and cheaper methods of improving cognitive functions in a subject using a lipid composition conjugated with omega-3 and omega-6 fatty acids, with specific amounts and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and eicosapentaenoyl (EPA), e.g. utilizing different sources of lipids.Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease.The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

The invention discloses a health care food composition capable of assisting in improving memory, and a preparation method of the composition. The health care food composition contains docosahexenoic acid (DHA) algal oil, gamma-aminobutyric acid, phosphatidylserine, taurine, zinc gluconate, vitamin C and vitamin B12. The invention also discloses the preparation method of the health care food composition. The animal function test proves that the health care food composition has the function of assisting in improving memory, and is free from toxic and side effects.

Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease. The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

The invention provides a tablet candy and a producing method thereof. The tablet candy is made of the following raw materials according to weight percent: 73.9-85% of sorbitol, 2-5% of flaxseed powder, 0.1-0.3% of L-theanine, 0.1-0.5% of gamma-aminobutyric acid, 0.5-2% of phosphatidylserine, 5-10% of xylitol, 0.1-0.3% of sucralose, 0-5% of flavoring essence, 0-0.1% of colorant, and 1-3% of magnesium stearate. In the tablet candy of the invention, flaxseed powder, L-theanine, gamma-aminobutyric acid and phosphatidylserine interwork according to certain proportion and in synergy, promote mutually, can effectively relieve pressure, tranquillize mood, calm sentiments, and improve memory and thinking capability, so that the tablet candy has health care functions of relieving pressure, relaxingmood, enhancing memory and the like, and is suitable to be eaten by common people as well as diabetics, obese people or people hoping to reduce weight.

The invention discloses a health-care food with a function of enhancing immunity and memory. The food comprises the following components in percentage by weight: 60-85% of pea albumen powder, 10-20% of whey protein powder, 1.5-10% of DHA (Docosahexaenoic Acid) algae oil, 1-10% of phosphatidylserine and 0.5-1% of phospholipid. According to the invention, pea albumen and whey protein are mixed by a certain proportion by means of a complementarity principle of animal and vegetable proteins, so that the structural proportion and number of amino acids better meet the demand of human body to the benefit of improving the immunity of human body and promoting synthesis of cerebral proteins. Meanwhile, pea albumen and phospholipid are matched in used to improve blood environment and prevent and treat lapse of memory caused by insufficient oxygen and blood supply to the brain. DHA and phosphatidylserine compounded have the correlating and prompting effect in the metabolic process of the brain of human body so as to enhance the memory and the like, so that the health-care food disclosed by the invention has the function of enhancing the immunity of human body and improving the memory of human body.

The invention relates to a stable preparation of phosphatidylserine and a preparation method, application as well as an application product of the stable preparation. The preparation method comprises the following step of processing the phosphatidylserine through microencapsulation, micro-pelletization or liposome encapsulation. The stable preparation of the phosphatidylserine can be independently applied as a medicine or can be added into daily foods, drinks and health-care products, also has an important effect on health care of brains while guaranteeing the color and the taste of the daily foods and the drinks of people and is of great benefit to brain disorder such as nutritional supplement of brain development of students, overstrain of nerves of the adults, and memory loss, brain atrophy and senile dementia of the middle aged and elderly people.

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

Disclosed are stable PS preparations, in powder, liquid and dispersion forms, as well as methods of producing thereof. Most importantly, the stable PS preparations are particularly devoid of residual phospholipase D activity, and the methods of eliminating such activity are also described herein. Lastly, uses of these PS preparations in nutraceuticals or as active agents of pharmaceutical compositions are also provided herein.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fusions, abbreviated ANV:KPI, utilize ANV having high affinity for phosphatidyl-L-serine with various KPI's to target serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. ANV:KPIs are potentially useful antithrombotic drugs permitting localized passivation of thrombogenic vessel walls and associated thrombi.

The invention discloses a method for finishing fabric through plant essential oil thermosensitive liposomes. The method comprises the following steps: mixing and stirring tea tree essential oil, menthol and artemisia vulgaris oil to obtain a natural fragrant antibacterial agent; dissolving the natural fragrant antibacterial agent in a phosphate buffered solution; mixing natural phosphatide, phosphatidylcholine, glyceryl phosphatide, phosphatidyl ethanolamine, phosphatidylserine and phosphatidic acid, adding cholesterol, dissolving the mixture into chloroform, pouring into a container, and evaporating at the room temperature until a layer of uniform thin film is formed on the container wall; adding the phosphate buffered solution of the natural fragrant antibacterial agent into the container coated with the thin film in ultrasonic water bath, and performing ultrasonic oscillation to obtain a thermosensitive liposome suspension liquor; adding an adhesive into the thermosensitive liposome suspension liquor, and stirring at the room temperature until the adhesive agent is completely dissolved, so as to obtain a thermosensitive fragrant antibacterial finishing agent; immersing and rolling fabric into the finishing liquid, immersing and rolling for the second time, and finally finishing and shaping the fabric by adopting a freezing and drying method.

Phosphatidylserine is extracted from animal brains by: drying animal brains, smashing them into granules, putting propanone into the granules, stirring and extracting, separating propanone supernatant liquid contained cholesterine and oils from the brain granules, steaming the residues to be dried, adding n-hexane or alcohol or ammonia water alcohol into steamed dry residues, stirring and extracting, separating extracting liquid contained phospholipid compositions, steaming the residues again, putting ether into steamed dry residues, stirring, freezing and defreezing, filtering to remove deposits, removing the remained phospholipid further, adjusting supernatant liquid pH=3-6, steaming to remove ether, and steaming to dry crude phosphatidylserine again, dissolving crude phosphatidylserine dry powders in n-hexane, adding sodium acetate alcohol liquid, stirring, settling to be laminated, removing the supernatant contained inositol phospholipid, finally, steaming to dry the n-hexane in supernatant liquid to obtain high pure phosphatidylserine under reduced pressure.

The invention relates to a method of preparing compounds, in particular to a method of preparing powder phosphatidylserine. The invention has to overcome the problems that the prior art inputs a lot of equipment and costs a lot, and the transformation ratio of the reaction is hard to be guaranteed. The invention has the technical proposal that a method of preparing powder phosphatidylserine takes natural lecithin as the reaction substrate; and after being separated by water, the reaction substrate can be added with an inorganic system prepared by L-serine, calcium salt and buffer solution to produce rough product under the effect of phospholipase D. Concentrate can be obtained by conducting the solvent extraction to the rough product, and then can be purified by solvent to obtain phosphatidylserine. The invention is characterized in that to separate the reaction substrate needs water three to ten times (w / v) of reaction substrate; and the separating temperature is ranged from 20 DEG C to 60 DEG C. In the system, the weight of the L-serine is two to ten times of the reaction substrate, and the weight of water used in the inorganic system is three to ten times(w / v) of reaction substrate. Ph value of the inorganic system can be adjusted between 4.5 and 6.0 by the buffer solution.

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.

Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically in the treatment of aged skin, and may include phosphatidylserine, vitamins, and other beneficial anti-aging ingredients.

The invention provides an extraction process of phosphatidylcholine with antarctic krill as a source. The extraction process comprises the following steps: collecting heads of the antarctic krill, adding water for decoction, stirring, sending the krill head decoction liquid to a cold pressing machine for solid-liquid separation, to obtain an oily liquid rich in phospholipid and krill heads and other solids; adding absolute ethyl alcohol into the krill heads and other solids, carrying out high shearing extraction, carrying out centrifugal separation, and concentrating to obtain an oily liquid; merging the oily liquids, drying under a reduced pressure, then filtering through a plate frame filter to remove insoluble substances, followed by carrying out membrane separation and concentration, carrying out column chromatography separation and purification, carrying out freeze drying, and thus obtaining the phosphatidylcholine product. The invention also provides a preparation method for phosphatidylserine with the antarctic krill as the source. The preparation method comprises the steps of hydrolyzing the extracted phosphatidylcholine by phospholipase D, and extracting to obtain phosphatidylserine rich in DHA and EPA. The extraction process and the preparation method are environmentally friendly, and are low in cost; and the obtained products have high content and good activity, and can be industrially produced.

Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein.

Dietary compositions are disclosed herein. For example, dietary compositions containing a combination of a phosphatidylserine, DHA, EPA, antioxidants, and Ginkgo Biloba are provided.

The invention discloses a pressed candy rich in phospholipid and phosphatidylserine. The pressed candy is prepared from, by weight, 50-150 parts of modified soybean lecithin, 50-150 parts of phosphatidylserine, 25-75 parts of vitamin C, 85-255 parts of isomaltitol, 12.5-37.5 parts of sorbitol, 0.25-7.5 parts of magnesium stearate and 25-75 parts of microcrystalline cellulose. The invention further discloses a preparation method of the pressed candy. According to the pressed candy, the formula is reasonable, the synergistic interaction of the components is achieved, the requirement for nutrients required by the brain can be met, the memory is remarkably improved, no side effects exist, the preparation technology is simple, and energy consumption can be reduced.

Disclosed are surprising new methods and compositions for isolating extracellular microvesicles such as exosomes, particularly disease-related and phosphatidylserine (PS)-positive extracellular microvesicles as exemplified by tumor- and viral-derived exosomes. The methods of the invention are rapid, efficient, cost-effective and, importantly, are suitable for use with large volumes of biological fluids and produce antigenically intact extracellular microvesicles and exosomes. The methods and compositions are based on the surprising use of acetate buffers to isolate large quantities of extracellular microvesicles, particularly tumor-derived exosomes, from solution, without damaging their morphological or functional properties or antigenicity.

A novel method of producing PS is described herein. The method first involves producing PLD enzyme through the use of enzyme-producing microorganisms. The PLD enzyme is reacted with a lecithin and source of serine to produce the phosphatidylserine (PS). The method differs from prior methods in several ways. First, it incorporates a novel strain of PLD enzyme-producing organism in a preferred embodiment. It is also the first known PS production method that allows for the reuse of the enzyme and serine components to enhance efficiency and productivity. It further incorporates a novel solvent system, unique stabilization agents for the PLD enzyme, as well as optimized reaction conditions.

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.

Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically in the treatment of aged skin, and may include phosphatidylserine, vitamins, and other beneficial anti-aging ingredients.

The invention relates to a method for preparing phosphatidylserine (2-DHA-PS) with docosahexaenoic acid at the sn-2 bit through high-activity phospholipase A2 and high-activity phospholipase D. Directed evolution is achieved through the overlapping PCR technology so that the high-activity phospholipase A2 and the high-activity phospholipase D can be obtained; the 2-DHA-PS is prepared through catalysis by means of the high-activity phospholipase A2 and the high-activity phospholipase D, phosphatidylserine is generated through phosphatidylcholine and serine under the catalysis of the high-activity phospholipase D first, and then the 2-DHA-PS is generated through the phosphatidylserine and the docosahexaenoic acid under the catalysis of the high-activity phospholipase A2. The relative content of the 2-DHA-PS in the product synthesized through the method is high, and the defects of an existing synthesizing method are effectively overcome.

A dietary supplemental composition composed of Acetyl-L-Carnitine, Phosphatidylserine, L-Alpha-Glycerylphosphorylcholine, fish oils including Docosahexaenoic acid, Alpha Lipoic Acid, and optionally Eicosapentaenoic acid, and which in combination has been demonstrated to be effective in increasing cognitive performance, elevating mood and decreasing oxidative stress levels in mammals.